Persistent choreoathetosis in a fatal olanzapine overdose: Drug kinetics, neuroimaging, and neuropathology

American Journal of Psychiatry

Volumn 162, Issue 1, 2005, Pages 28-33

  Davis, Larry E ^a   Becher, Mark W ^b   Tlomak, Wieslawa ^b   Benson, Blaine E ^b   Lee, Roland R ^b   Fisher, Ellen C ^b  

^a NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; BENZATROPINE; CHARCOAL; CLOZAPINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; HALOPERIDOL; HISTAMINE H1 RECEPTOR; IBUPROFEN; LITHIUM; LORAZEPAM; METHOCARBAMOL; MORPHINE; MUSCARINIC RECEPTOR; OLANZAPINE; QUETIAPINE; RABEPRAZOLE; RISPERIDONE; SEROTONIN 2 RECEPTOR; SEROTONIN 6 RECEPTOR; SODIUM CHLORIDE; TERAZOSIN; THIAMINE;

ADULT; AGGRESSION; AKATHISIA; AUTOPSY; BINDING AFFINITY; BIPOLAR DISORDER; BRAIN ATROPHY; CARDIOPULMONARY ARREST; CASE REPORT; CHOREOATHETOSIS; COMA; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONFUSION; CONSCIOUSNESS; DELIRIUM; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG OVERDOSE; DYSTONIA; ELECTROENCEPHALOGRAM; EPILEPTIC STATE; EXTRAPYRAMIDAL SYNDROME; HEART ARRHYTHMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL ADMISSION; HUMAN; HYPERSALIVATION; LETHARGY; MALE; MANIA; MENTAL DETERIORATION; MORTALITY; MUTISM; NEUROIMAGING; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSESSIVE COMPULSIVE DISORDER; PARANOIA; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SEIZURE; SUICIDE ATTEMPT; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; TRACHEOSTOMY;

ANTIPSYCHOTIC AGENTS; ATHETOSIS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; BRAIN; CHOREA; DIFFUSION MAGNETIC RESONANCE IMAGING; FATAL OUTCOME; HUMANS; MALE; MIDDLE AGED; OVERDOSE;

EID: 11844257561     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.162.1.28     Document Type: Conference Paper

References (35)

1. Mulligan K: Antipsychotic comparison finds surprising result. Psychiatr News, July 4, 2003, pp 14, 38
2. Bymaster FP, Perry KW, Nelson DL, Wong DT, Rassmussen K, Moore NA, Calligaro DO: Olanzapine: a basic science update. Br J Psychiatry 1999; 174(suppl 37):36-40
3. Bever KA, Perry PJ: Olanzapine: a serotonin-dopamine-receptor antagonist for antipsychotic therapy. Am J Health Syst Pharm 1998; 55:1003-1016
4. Beasley CM, Tollefson GD, Tran PV: Safety of Olanzapine. J Clin Psychiatry 1997; 58(suppl 10):13-17
5. Wyderski RJ, Starrett WG, Abou-Saif A: Fatal status epilepticus associated with Olanzapine therapy. Ann Pharmacother 1999; 33:787-789
6. Perkins DO, McClure RK: Hypersalivation coincident with olanzapine treatment (letter). Am J Psychiatry 1998; 155:993-994
7. Sheitman BB, Lindgren JC, Early J, Sved M: High-dose olanzapine for treatment-refractory schizophrenia (letter). Am J Psychiatry 1997; 154:1626
8. Cohen LG, Fatalo A, Thompson BT, Di Centes Bergerson G, Flood JG, Poupolo PR: Olanzapine overdose with serum concentrations. Ann Emerg Med 1999; 34:275-278
9. Chambers RA, Caracansi A, Weiss G: Olanzapine overdose cause of acute extrapyramidal symptoms (letter). Am J Psychiatry 1998; 155:1630-1631
10. Zyprexa - Overdose Safety Profile. Indianapolis, Eli Lilly and Co, 2003
11. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R: Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159:561-566
12. Litovitz T, Klein-Schwartz W, White S, Cobaugh DJ, Youniss J, Omslaer J, Drab A, Benson BE: 2000 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2001; 19:337-395
13. Litovitz T, Klein-Schwartz W, Rogers GC, Cobaugh DJ, Youniss J, Omslaer J, Drab A, May ME, Woolf AD, Benson BE: 2001 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2002; 20: 391-452
14. Watson WA, Litovitz T, Rogers GC, Klein-Schwartz W, Youniss J, Omslaer J, Rose SR, Borys D, May ME: 2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2003; 21:353-421
15. Merrick TC, Felo JA, Jenkins AJ: Tissue distribution of olanzapine in a postmortem case. Am J Forensic Med Pathol 2001; 22:270-274
16. Gerber JE, Cawthon B: Overdose and death with olanzapine: two case reports. Am J Forensic Med Pathol 2000; 21:249-251
17. Stephens BG, Coleman DE, Baselt RC: Olanzapine-related fatality. J Forensic Sci 1998; 43:1252-1253
18. Catlow JT, Barton RD, Clemens M, Gillespie TA, Goodwin M, Swanson SP: Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 1995; 668:85-90
19. Dunne JW, Summers QA, Stewart-Wynne EG: Non-convulsive status epilepticus: a prospective study in an adult general hospital. Q J Med 1987; 238:117-126
20. Towne AR, Waterhouse EJ, Boggs JG, Garnett LK, Brown AJ, Smith JR Jr, DeLorenzo RJ: Prevalence of nonconvulsive status epilepticus in comatose patients. Neurology 2000; 54:340-345
21. Drislane FW: Evidence against permanent neurologic damage from nonconvulsive status epilepticus. J Clin Neurophysiol 1999; 16:323-331
22. Sperling MR, Wilson G, Engel J, Babb TL, Phelps M, Bradley W: Magnetic resonance imaging in intractable partial epilepsy: correlative studies. Ann Neurol 1986; 20:57-62
23. Kogoj A, Velikonja I: Olanzapine induced neuroleptic malignant syndrome - a case review. Hum Psychopharmacol Clin Exp 2003; 18:301-309
24. Adnet P, Lestavel P, Krivosic-Horber R: Neuroleptic malignant syndrome. Br J Anaesth 2000; 85:129-135
25. Elian AA: Fatal overdose of olanzapine. Forensic Sci Int 1998; 16:231-235
26. Robertson MD, McMullin MM: Olanzapine concentrations in clinical serum and postmortem blood specimens - when does therapeutic become toxic? J Forensic Sci 2000; 45:418-421
27. Jenkins AJ, Sarconi KM, Raaf HN: Determination of olanzapine in a postmortem case. J Anal Toxicol 1998; 22:605-609
28. Fulton B, Goa KL: Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 1997; 53:282-298
29. Aravagiri M, Teper Y, Marder SR: Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 1999; 20:369-377
30. Filion M: Physiologic basis of dyskinesia. Ann Neurol 2000; 47(suppl 1):S35-S41
31. Fahn S: The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000; 47(suppl 1):S2-S11
32. Li XM, Perry KW, Wong DT, Bymaster FP: Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology (Berl) 1998; 136:153-161
33. Stockton ME, Rassmussen K: Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 1996; 14:97-104
34. Montenegro MA, Scontoni AE, Cendes F: Dyskinesia induced by phenytoin. Arq Neuropsiquiatr 2000; 57:356-360
35. Saito Y, Oguni H, Awaya Y, Hayashi K, Osawa M: Phenytoin-induced choreoathetosis in patients with severe myoclonic epilepsy in infancy. Neuropediatrics 2001; 32:231-235